Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Roche on Its Sale of Florence, South Carolina, Manufacturing Site to Patheon
Davis Polk is advising Roche Holding Ltd. in connection with the sale of an active pharmaceutical ingredients manufacturing…
Abbott Laboratories $15.1 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $2.85 billion…
AbbVie Inc. €3.6 Billion Senior Notes Offering
Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of …
Merck €1 Billion Notes Offering
Davis Polk advised the representatives of the underwriters, in connection with the offering of €1 billion aggregate…
Theravance Biopharma, Inc. Concurrent Ordinary Shares and Convertible Senior Notes Offerings
Davis Polk advised the joint book-running managers in connection with a $100.1 million SEC-registered offering of 3,850…
Davis Polk Advises Roche Holdings on Its $1.5 Billion Notes Offering
Davis Polk advised Roche Holdings, Inc. in connection with its Rule 144A/Regulation S offering of $650 million aggregate…
iRhythm Technologies, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the initial public…
Davis Polk Advises Advanced Accelerator Applications S.A. on Its Follow-On Offering
Davis Polk advised Advanced Accelerator Applications S.A. on its approximately $150 million SEC-registered follow-on…
Versartis Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $60 million follow-on offering of 4,898,000 shares…
Davis Polk Advises AC Immune SA on Its Initial Public Offering
Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000…